Benchmarking Histopathology Foundation Models for Ovarian Cancer Bevacizumab Treatment Response Prediction from Whole Slide Images

Abstract

Bevacizumab Treatment Response Prediction from Whole Slide Images Authors: ['Mayur Mallya' 'Ali Khajegili Mirabadi' 'Hossein Farahani' 'Ali Bashashati'] Purpose: Bevacizumab is a widely studied targeted therapeutic drug used in conjunction with standard chemotherapy for the treatment of recurrent ovarian cancer. While its administration has shown to increase the progression-free survival (PFS) in patients with advanced stage ovarian cancer, the lack of identifiable biomarkers for predicting patient response has been a major roadblock in its effective adoption towards personalized medicine. Methods: In this work, we leverage the latest histopathology foundation models trained on large-scale whole slide image (WSI) datasets to extract ovarian tumor tissue features for predicting bevacizumab response from WSIs. Results: Our extensive experiments across a combination of different histopathology foundation models and multiple instance learning (MIL) strategies demonstrate capability of these large models in predicting bevacizumab response in ovarian cancer patients with the best models